The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Chronic Myelomonocytic Leukemia: Diagnosis and Management

MDS/MPN overlap disorder with persistent monocytosis and varied clinical course

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Chronic Myelomonocytic Leukemia: Diagnosis and Management?

CMML is classified as a myelodysplastic/myeloproliferative neoplasm overlap syndrome with persistent monocytosis greater than 1×10⁹/L and over 10 percent of leukocytes.

Subclassification distinguishes CMML-0 (less than 2 percent blasts), CMML-1 (2 to 4 percent blasts) and CMML-2 (5 to 19 percent blasts) based on bone marrow and peripheral blast counts.

Clinical phenotypes include myelodysplastic-like (MD-CMML, white blood cell count below 13×10⁹/L) and myeloproliferative-like (MP-CMML, count above 13×10⁹/L) with prognostic implications.

Recurrent mutations include TET2, SRSF2, ASXL1, RUNX1 and signaling pathway mutations affecting RAS, JAK2 and CBL pathways.

CMML-specific prognostic models including CPSS-Mol incorporate molecular features for refined risk assessment.

Symptoms

Fatigue, weakness and constitutional symptoms from cytopenias and underlying disease.
Splenomegaly with abdominal discomfort, early satiety in approximately 50 percent of patients.
Recurrent infections related to functional defects despite normal or elevated white blood cell counts.
Bleeding manifestations from thrombocytopenia or platelet dysfunction.
Skin involvement including leukemia cutis or other paraneoplastic dermatoses in some patients.

Risk Factors

Older age with median age at diagnosis approximately 70 years and male predominance.
Prior cytotoxic therapy or radiation exposure as therapy-related CMML.
Environmental exposures including benzene, agricultural chemicals and other toxins.
Co-existing autoimmune or inflammatory conditions in some patients.
Specific germline predisposition with familial cases involving TET2 or other myeloid genes.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent peripheral blood monocytosis greater than 1×10⁹/L lasting more than 3 months requires hematologic evaluation.
  • Unexplained cytopenias with monocytosis or splenomegaly warrants prompt specialty referral.
  • Newly diagnosed CMML requires comprehensive workup including bone marrow examination, cytogenetics and molecular testing.
  • Worsening cytopenias, increasing splenomegaly or transformation suspected to AML need urgent reassessment.
  • Long-term hematologic follow-up is essential for monitoring disease progression and treatment response.

Treatment Methods

01
Asymptomatic patients with low-risk disease may be managed with watchful waiting and supportive care.
02
Hypomethylating agents including azacitidine and decitabine are standard for higher-risk CMML providing improved cytopenias and survival benefit.
03
Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for eligible higher-risk patients.
04
Cytoreductive therapy with hydroxyurea for symptomatic leukocytosis or splenomegaly in proliferative-type CMML.
05
Comprehensive care including risk-adapted treatment selection, supportive transfusions, infection prevention, monitoring for AML transformation, clinical trial enrollment and management of complications optimize outcomes in this heterogeneous disorder.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.